Pieris Pharmaceuticals, Inc.

Equities

PIRS

US7207952026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
6.85 ^USD	+4.90%		-18.45%	-52.95%

Jul. 03	Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH, es Laboratoires Servier and Institut de Recherches Internationales Servier Announce Termination of A Material Definitive Agreement	CI
May. 15	Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

PIERIS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 03, 2022 at 07:06 am EST

Item 8.01 Other Events.

On January 3, 2022, the Company issued a press release announcing the successful completion of the sponsor safety review of part 1a of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated PRS-060/AZD14022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release, Dated January 3, 2022 .

--------------------------------------------------------------------------------

Latest news about Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH, es Laboratoires Servier and Institut de Recherches Internationales Servier Announce Termination of A Material Definitive Agreement	Jul. 03	CI
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	Apr. 19	MT
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	Jan. 05	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Stock Futures -2-	Nov. 08	DJ
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from S&P Global BMI Index	23-09-18	CI
Vicore Pharma's New CEO to Formally Take Office	23-09-08	MT
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	23-09-01	MT
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	23-08-17	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
Pieris to Cut 70% Workforce, Hires Advisor For Strategic Review; AstraZeneca to End R&D Deal	23-07-18	MT
Pieris Pharmaceuticals to Explore Strategic Options	23-07-18	CI
Pieris Pharmaceuticals, Inc. Announces Executive Changes	23-07-13	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell Microcap Growth Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell Microcap Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index	23-06-23	CI
Sector Update: Health Care Stocks Steady to Higher Late Wednesday	23-06-21	MT

Chart Pieris Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Companyâs clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
PIERIS PHARMACEUTICALS, INC.	-52.95%	9.04M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs